-
UPDATE: JP Morgan Lowers PT on Gen-Probe from $85 to $64
Friday, July 29, 2011 - 8:47am | 88J.P. Morgan has published a report on Gen-Probe (NASDAQ: GPRO) lowering the price target from $85.00 to $64.00. In the report, J.P. Morgan wrote, "2Q11 results were better than many had feared, in light of the difficult quarter for healthcare utilization-exposed companies (QGEN, DGX, HCA),...
-
Morgan Keegan Upgrades Hill-Rom Holdings To Outperform
Friday, July 29, 2011 - 8:40am | 60According to Morgan Keegan, Hill-Rom Holdings (NYSE: HRC) is upgraded to Outperform. Morgan Keegan said that it is raising its rating on Hill-Rom shares to Outperform from Market Perform. “We have slightly reduced our price target to $45 from $48 to account for slightly lower EPS estimates for...
-
Jefferies Reiterates Buy on Integra LifeSciences, Slashes PT to $55
Friday, July 29, 2011 - 8:17am | 47Jefferies reiterated its Buy rating on Integra LifeSciences (NASDAQ: IART). At the same time, the rating agency reduced its price target on the company's stock from $58 to $55. On Thursday, IART added 0.28% to its value to end the day at $45.85.
-
UPDATE: Citi Lowers PT on Boston Scientific to $7.30
Friday, July 29, 2011 - 8:08am | 73Citi is out with its report today on Boston Scientific (NYSE: BSX), lowering its PT from $7.40 to $7.30. In its report, Citi writes, "We arrive at our $7.30 target price using a rounded up average of two valuations: 1) an 11.6x multiple off our 2012 cash EPS of $0.71 and 2) a TEV/EBITDA 7.2x...
-
News Summary for July 29, 2011
Friday, July 29, 2011 - 7:52am | 542This is your Benzinga news summary and traders' outlook for Friday, July 29, 2011, covering headlines from overnight and Friday's pre-market session. Today in domestic pre-market trading, U.S. equity futures are trading lower as traders worry about when the decision on the debt ceiling will be...
-
J.P. Morgan Underweight On Boston Scientific Corporation
Friday, July 29, 2011 - 7:37am | 143J.P. Morgan Chase & Co. is out with a research report on Boston Scientific Corporation (NYSE: BSX) and it has a Underweight rating and a $8 price target on shares after it reported earnings. In a note to clients, J.P. Morgan Chase & Co. writes, "For 2012, we are trimming our revenue...
-
Benchmark Rating and PT Updates 7/29
Friday, July 29, 2011 - 7:20am | 346Benchmark made a number of rating and price target updates in a research report published today. CryoLife (NYSE: CRY) had its rating upgraded from Hold to Buy. Its price target was maintained at $6.50. On Thursday, CRY lost 1.99% of its value to finish the day at $5.42. Expedia (NASDAQ: EXPE)...
-
Morgan Stanley Comments on Performance at Boston Scientific
Friday, July 29, 2011 - 7:11am | 94Morgan Stanley has published a report on Boston Scientifics (NYSE: BSX) outlining general operating numbers for the medical device developer. In the report, Morgan Stanley wrote, "Revenue and margin uncertainty keep us from a more constructive outlook despite progress on cost initiatives and the...
-
Benzinga's Top Upgrades
Friday, July 29, 2011 - 7:09am | 122Analysts at Morgan Keegan upgraded Whiting Petroleum Corporation (NYSE: WLL) from “market perform” to “outperform.” WLL's shares closed at $55.76 yesterday. Whiting Petroleum's PEG ratio is 0.81. McAdams Wright Ragen upgraded PACCAR Inc (NASDAQ: PCAR) from “hold” to “buy.” PACCAR's shares closed...
-
Morgan Stanley Comments on Mergers and Acquisitions at Integra Lifesciences
Friday, July 29, 2011 - 7:01am | 129Morgan Stanley has published a report on Integra LifeSciences (NASDAQ: IART) commenting on mergers and acquisitions by the medical device company. In the report, Morgan Stanley wrote, "After an uneventful yet positive quarter, we question whether getting bigger is the best way to improve...
-
Jefferies Lowers PT on Integra Life-Sciences To $55
Friday, July 29, 2011 - 6:58am | 27Jefferies & Company has lowered the price target on Integra Life-Sciences (NASDAQ: IART) from $58 to $55 and maintains its Buy rating.
-
Morgan Keegan Upgrades Hill-Rom To Outperform, Lowers PT To $45
Friday, July 29, 2011 - 6:43am | 29Morgan Keegan has upgraded Hill-Rom Holdings (NYSE: HRC) from Market Perform to Outperform and has lowered the price target from $48 to $45.
-
Citigroup Lowers PT on Boston Scientific To $7.30
Friday, July 29, 2011 - 6:17am | 27Citigroup has lowered the price target on Boston Scientific Corporation (NYSE: BSX) from $7.40 to $7.30 and maintains its Hold rating.
-
JP Morgan Lowers PT On Gen-Probe To $64
Friday, July 29, 2011 - 5:59am | 26JP Morgan has lowered the price target on Gen-Probe (NASDAQ: GPRO) from $85 to $64 and maintains its Neutral rating.
-
Benchmark Upgrades Cryolife To Buy, $6.50 PT
Friday, July 29, 2011 - 5:50am | 26The Benchmark Company has upgraded Cryolife (NYSE: CRY) from Hold to Buy and has established a $6.50 price target.